Drug recall · January 15, 2020
Glenmark Ranitidine Tablets USP 150 mg recall
Why: CGMP Deviations: Presence of NDMA impurity detected in product.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Glenmark Ranitidine Tablets USP 150 mg Rx Only 60 Tablets Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale-Bandez, Goa 403513, India Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ NDC 68462-248-60
- Lots / codes
7701164A 7701471A 7701670B 7701827A 7702242A 7702705A 7702947A 7703408A 7704494A 7704495A 19190289 19190342 19190372 7702737A
- Quantity
- 208,668 bottles
- Company
- Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ
- Distribution
- Natiowide
- Initiated
- December 17, 2019 · Voluntary: Firm initiated
- Classified
- January 5, 2020
- Reported
- January 15, 2020
- How notified
- Press Release
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Ranitidine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.